<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[ep vantage Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/ep+vantage.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to ep vantage]]></description>
	<s:counts start="0" returned="20" found="35" />
	<language>en-us</language>
	<item>
		<title><![CDATA[High Hopes Remain for Celgene's Revlimid]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F177376-high-hopes-remain-for-celgene-s-revlimid%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: Hotly anticipated data from a big trial of Celgene&#8217;s CELG Revlimid in multiple myeloma were released at the American Society of Hematology Ash yesterday and, as is often the case, prompted more questions that answers. This is partly because the study, called MM-015, has not finished yet,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 09 Dec 2009 09:08:16 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">CELG,JNJ</category>
	</item>
	<item>
		<title><![CDATA[Celgene's Gloucester Buy: Finding Opportunity in Blood Cancer Treatment]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F176935-celgene-s-gloucester-buy-finding-opportunity-in-blood-cancer-treatment%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: Gloucester Pharmaceuticals promised a deal by the beginning of next year and today delivered early and in style with a takeover offer worth up to $640 million from Celgene CELG.               Speaking last month...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 07 Dec 2009 10:47:25 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/allos+therapeutics+inc..html"><![CDATA[Allos Therapeutics Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ALTH</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="tickers">ALTH,CELG</category>
	</item>
	<item>
		<title><![CDATA[Merck KGaA: Another Stumble Leaves Investors Worried]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175962-merck-kgaa-another-stumble-leaves-investors-worried%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: It was the kind of news that Merck KGaA (MKGAY.PK) could have done without following its failure last week to get European approval for Erbitux in lung cancer.  As such, the bombshell that the FDA had issued a refuse to file letter in response to the...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 01 Dec 2009 09:08:22 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Genzyme's Very Bad Year]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174932-genzyme-s-very-bad-year%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: Even before the FDA&#8217;s ominous announcement last week that it had found things that really should not be there in vials of Genzyme&#8217;s GENZ enzyme replacement products, the US biotech was certainly having a personal annus horribilis.          ...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 23 Nov 2009 01:32:12 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/genzyme+corp..html"><![CDATA[Genzyme Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/isis+pharmaceuticals+inc..html"><![CDATA[Isis Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GENZ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ISIS</category>
		<category domain="tickers">GENZ,ISIS</category>
	</item>
	<item>
		<title><![CDATA[NeurogesX: Next Stop, U.S. Market]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174357-neurogesx-next-stop-u-s-market%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: The final piece of the puzzle fell into place for NeurogesX NGSX earlier this week when the FDA granted approval for its pain patch, Qutenza, to treat postherpetic neuralgia PHN. The company and its investors&#8217; attention will now turn to commercialisation, a process that throws up a...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 19 Nov 2009 10:33:24 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/neurogesx+inc..html"><![CDATA[NeurogesX Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NGSX</category>
		<category domain="tickers">NGSX</category>
	</item>
	<item>
		<title><![CDATA[Poniard Pharmaceuticals' Gamble Doesn't Pay Off]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174080-poniard-pharmaceuticals-gamble-doesn-t-pay-off%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: Poniard Pharmaceuticals PARD on Monday stared into the abyss of disappointment. Shares in the US company lost three quarters of their value on news that its platinum-based chemotherapy agent, picoplatin, failed to improve overall survival in patients with lung cancer in a phase III trial, dashing hopes...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 18 Nov 2009 09:58:06 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/poniard+pharmaceuticals+inc..html"><![CDATA[Poniard Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
		<category domain="tickers">PARD</category>
	</item>
	<item>
		<title><![CDATA[Hemispherx Biopharma: Investors Growing Tired of CFS Drug Delays]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F172247-hemispherx-biopharma-investors-growing-tired-of-cfs-drug-delays%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: In what has definitely not been its finest week, Hemispherx Biopharma HEB has seen its shares fall heavily after being forced to admit that there were still several issues outstanding with its NDA filing for lead drug, Ampligen, that would mean essential paper work for getting approval...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 09 Nov 2009 09:44:18 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/hemispherx+biopharma+inc..html"><![CDATA[Hemispherx BioPharma Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HEB</category>
		<category domain="tickers">HEB</category>
	</item>
	<item>
		<title><![CDATA[XenoPort's Most Recent Data Points to Larger Opportunity]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F162179-xenoport-s-most-recent-data-points-to-larger-opportunity%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: XenoPort XNPT received a big boost  yesterday from positive data on its lead drug, GSK1838262/XP13512 gabapentin enacarbil, in a neuropathic pain trial, the second attempt by the company and its partner GlaxoSmithKline GSK to prove that this product has much larger potential than currently forecast. ...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 18 Sep 2009 01:31:14 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/xenoport+inc..html"><![CDATA[XenoPort Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">XNPT</category>
		<category domain="tickers">GSK,XNPT</category>
	</item>
	<item>
		<title><![CDATA[Glaxo's U.S. Cervarix Approval More Important for Company's Pride than for Sales]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F160957-glaxo-s-u-s-cervarix-approval-more-important-for-company-s-pride-than-for-sales%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: GlaxoSmithKline GSK finally appears set to win approval for its cervical  cancer vaccine Cervarix in the US, an event that could now occur in a couple of weeks' time and bring a long and tortuous journey to a conclusion. Having first filed the vaccine in March...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 11 Sep 2009 01:15:04 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">GSK,MRK</category>
	</item>
	<item>
		<title><![CDATA[Facet Biotech Should Dig in Its Heels over Biogen Bid]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F160334-facet-biotech-should-dig-in-its-heels-over-biogen-bid%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: While most shareholders would, under normal circumstance, jump at a takeover bid that carried a 64% premium, Facet Biotech FACT appears to be sensibly holding out for better terms following an unsolicited $355m approach from  Biogen Idec BIIB. Despite the initially impressive share price premium, the...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 08 Sep 2009 01:22:33 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/us+market.html"><![CDATA[US Market]]></category>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[Market Jitters Affect Allos]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F160156-market-jitters-affect-allos%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: Usually the endorsement of an FDA advisory panel for approval of your product is greeted with praise from analysts and an uplift in share price. Unfortunately for Allos Therapeutics ALTH, their 10-4 positive recommendation for pralatrexate, now known as Folotyn, for the hard-to-treat blood cancer, peripheral T-cell...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sun, 06 Sep 2009 04:08:26 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/allos+therapeutics+inc..html"><![CDATA[Allos Therapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ALTH</category>
		<category domain="tickers">ALTH</category>
	</item>
	<item>
		<title><![CDATA[Lilly's Arzoxifene Defeat: Pharma Giant's Pipeline Looks Awfully Dry Now]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F157244-lilly-s-arzoxifene-defeat-pharma-giant-s-pipeline-looks-awfully-dry-now%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: Eli Lilly LLY has finally admitted defeat in its long-running battle to make  arzoxifene, a follow-on osteoporosis drug to its own blockbuster Evista, an approvable and commercially viable product. Although the results of a pivotal phase III trial met its primary endpoints, the drug failed on...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 20 Aug 2009 04:09:42 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">AMGN,LLY</category>
	</item>
	<item>
		<title><![CDATA[Astellas' Current Setback Underscores Need for Pipeline Expansion]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F155871-astellas-current-setback-underscores-need-for-pipeline-expansion%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: The spectre of approval for generic versions of transplant drug Prograf, which has been stalking Astellas (ALPMF.PK) for some months now, has materialised in the realms of reality with news that  Novartis&#8217;s NVS Sandoz unit is about to launch a copycat version of the product in...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 13 Aug 2009 03:10:35 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Onyx Signaling Appetite for Deals]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F155333-onyx-signaling-appetite-for-deals%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: Onyx Pharmaceuticals ONXX ruffled some feathers last week by announcing a fundraising effort to raise around $300m, prompting shareholders to fret about what the already cash-rich company has planned. Vague talk about licensing opportunities by management, who refused to say what type of deals they were pursuing,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 11 Aug 2009 03:03:47 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/onyx+pharmaceuticals+inc..html"><![CDATA[Onyx Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ONXX</category>
		<category domain="tickers">ONXX</category>
	</item>
	<item>
		<title><![CDATA[ViroPharma Finally Able to Look Forward]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F154327-viropharma-finally-able-to-look-forward%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: ViroPharma VPHM has lost a long-fought battle to keep generic versions of its top selling antibiotic,  Vancocin, off the market, a disappointing outcome for the company, but one that was widely anticipated. The antibiotic has been hugely profitable for ViroPharma and a few more years of...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 06 Aug 2009 08:45:12 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/viropharma+inc..html"><![CDATA[ViroPharma Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VPHM</category>
		<category domain="tickers">VPHM</category>
	</item>
	<item>
		<title><![CDATA[Once Again, Savient Disappoints Investors]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F153542-once-again-savient-disappoints-investors%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: Savient SVNT once again demonstrated its ability to disappoint investors, yesterday announcing that the FDA has refused to grant its new gout treatment, Krystexxa, a marketing license. The news prompted shares in the company to plunge 30% in early trade. Even though no further trials have been...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 04 Aug 2009 03:57:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/savient+pharmaceuticals+inc..html"><![CDATA[Savient Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SVNT</category>
		<category domain="tickers">SVNT</category>
	</item>
	<item>
		<title><![CDATA[United Therapeutics: Gold Star Performance as Second FDA Approval Confirmed]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F153128-united-therapeutics-gold-star-performance-as-second-fda-approval-confirmed%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: If pharma companies had end of school awards before the summer holidays United Therapeutics UTHR would be lining up to get a well deserved gold star for achieving its goal of bagging two US approvals in the space of just eight weeks. On Friday, the FDA granted...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sun, 02 Aug 2009 03:54:53 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/united+therapeutics+corp..html"><![CDATA[United Therapeutics Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">UTHR</category>
		<category domain="tickers">UTHR</category>
	</item>
	<item>
		<title><![CDATA[Lundbeck's Late Stage Pipeline Keeps Looking Thinner]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F152823-lundbeck-s-late-stage-pipeline-keeps-looking-thinner%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: Lundbeck (HLUKY.PK) yesterday announced yet another setback to its late-stage pipeline, with the news that it and partner Solvay (SVYSY.PK) would be discontinuing development of anti-psychotic drug  bifeprunox.  While the news itself was not a massive surprise following an earlier failure of the drug as...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 31 Jul 2009 03:55:25 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
	</item>
	<item>
		<title><![CDATA[Human Genome Sciences Raises $310m on Huge Share Price]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F152818-human-genome-sciences-raises-310m-on-huge-share-price%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: Carpe diem appears to be the motto of the day for Human Genome Sciences HGSI, which is taking advantage of the huge share price rise it has experienced since announcing positive phase III data for its lupus drug, Benlysta, and raising up to $310m in a share...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 31 Jul 2009 03:36:16 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/human+genome+sciences+inc..html"><![CDATA[Human Genome Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HGSI</category>
		<category domain="tickers">HGSI</category>
	</item>
	<item>
		<title><![CDATA[King Pharma: FDA Headaches Continue]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F152817-king-pharma-fda-headaches-continue%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: As a pain company, King Pharmaceuticals KG might want to get working on a treatment to spare it the agony that the FDA appears intent on continuing to heap upon its head. Yesterday, an advisory committee voted 11-5 not to recommend its heart imaging drug  Corvue...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 31 Jul 2009 03:30:33 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/king+pharmaceuticals+inc..html"><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KG</category>
		<category domain="tickers">KG</category>
	</item>
</channel>
</rss>
